Konstantinos Nikolaos Syrigos

Konstantinos Nikolaos Syrigos's AcademicInfluence.com Rankings

Medical

#3019

World Rank

#3470

Historical Rank

Oncology

#205

World Rank

#213

Historical Rank

medical Degrees

Konstantinos Nikolaos Syrigos

Philosophy

#8700

World Rank

#12129

Historical Rank

Logic

#5730

World Rank

#7152

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Konstantinos Nikolaos Syrigos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Konstantinos Nikolaos Syrigos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (2019) (1372)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial (2014) (959)
Programmed death ligand-1 expression in non-small cell lung cancer (2014) (707)
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer (2013) (636)
Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action (2020) (415)
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. (2015) (367)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) (2006) (365)
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 (2020) (335)
Objective measurement and clinical significance of TILs in non-small cell lung cancer. (2015) (309)
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer (2012) (271)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. (2014) (223)
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer (2006) (208)
Circulating VEGF Levels in the Serum of Gastric Cancer Patients: Correlation With Pathological Variables, Patient Survival, and Tumor Surgery (2002) (187)
Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. (2001) (170)
Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies (2012) (160)
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis (2019) (144)
Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer (2018) (139)
Expression of catenins and E‐cadherin during epithelial restitution in inflammatory bowel disease (1998) (137)
Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. (2004) (134)
Lung cancer in never smokers: disease characteristics and risk factors. (2013) (129)
E‐cadherin/catenin complex in benign and malignant melanocytic lesions (1998) (129)
Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. (2001) (127)
Sex Hormone Changes in Morbidly Obese Patients after Vertical Banded Gastroplasty (1998) (126)
Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. (2013) (125)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer (2017) (121)
Sarcoidosis‐Like Reactions Induced by Checkpoint Inhibitors (2018) (114)
E‐cadherin expression in bladder cancer using formalin‐fixed, paraffin‐embedded tissues: Correlation with histopathological grade, tumour stage and survival (1995) (114)
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. (2009) (106)
Targeted therapies for non-small cell lung cancer. (2007) (103)
Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer (2006) (100)
Biodistribution and pharmacokinetics of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies (2000) (100)
Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. (2003) (98)
mTOR pathway: A current, up-to-date mini-review (Review) (2014) (98)
Analytic Variability in Immunohistochemistry Biomarker Studies (2010) (96)
Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model (2000) (94)
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling (2019) (91)
Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. (1999) (90)
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes (2017) (90)
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton (2007) (88)
Clinical Significance of Serum Levels of E-Selectin, Intercellular Adhesion Molecule-1, and Vascular Cell Adhesion Molecule-1 in Gastric Cancer Patients (2003) (86)
Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. (1998) (85)
Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. (2015) (84)
Venous thromboembolism in COVID-19: A systematic review and meta-analysis (2021) (80)
Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. (2000) (79)
Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. (2002) (79)
Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. (2000) (79)
The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis. (2014) (79)
Clinical significance of heat shock protein-70 expression in bladder cancer. (2003) (78)
Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. (1998) (78)
In vitro cytotoxicity following specific activation of amygdalin by β‐glucosidase conjugated to a bladder cancer‐associated monoclonal antibody (1998) (73)
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations (2018) (70)
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. (2010) (68)
The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). (2008) (68)
The VEGF pathway in lung cancer (2013) (67)
Liposomally targeted cytotoxic drugs for the treatment of cancer (2002) (67)
Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. (2009) (65)
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis (2012) (65)
Hormones of adipose tissue and their biologic role in lung cancer. (2014) (60)
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. (2008) (58)
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. (2004) (58)
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology (2010) (58)
MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis (2014) (58)
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer (2012) (57)
Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review (2014) (57)
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway (2012) (57)
Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma (1998) (55)
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study (2004) (54)
Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. (2021) (51)
E-cadherin expression correlates with tumor differentiation in colorectal cancer. (1999) (51)
Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. (2001) (50)
Prostate cancer in the elderly. (2005) (50)
Role of adhesion molecules in bladder cancer: an important part of the jigsaw. (1999) (48)
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial (2018) (48)
Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. (2016) (46)
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. (2013) (46)
E-cadherin expression as a differentiation marker in gastric cancer. (1998) (45)
Survival and Quality of Life Benefit after Endoscopic Management of Malignant Central Airway Obstruction (2016) (44)
Immunotherapy for pancreatic cancer (2016) (44)
Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer. (2012) (44)
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. (2004) (43)
Breast angiosarcoma that is not related to radiation exposure: A comprehensive review of the literature (2011) (39)
Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study (2005) (39)
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study (2005) (39)
Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study (2020) (38)
Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus. (1999) (38)
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. (2008) (38)
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. (2016) (38)
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. (2010) (37)
Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review (2014) (37)
Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience. (2005) (37)
Prostate cancer chemotherapy in the era of targeted therapy (2009) (37)
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma (2009) (37)
Circulating tumor cells count as a predictor of survival in lung cancer. (2018) (36)
Gemcitabine versus Gemcitabine–Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group (2007) (36)
Analgesic efficacy of an ibuprofen-releasing foam dressing compared with local best practice for painful exuding wounds. (2011) (36)
Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non--small-cell lung cancer. (2012) (34)
Abnormal expression of p120 correlates with poor survival in patients with bladder cancer. (1998) (34)
Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. (1997) (34)
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma (2012) (33)
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. (2010) (33)
Interleukin-7 and Interleukin-15 for Cancer (2014) (33)
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. (2017) (33)
Multimodal treatment strategies for elderly patients with head and neck cancer. (2014) (33)
Expression patterns of the E-cadherin-catenin cell-cell adhesion complex in gastric cancer. (2000) (32)
Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors (2016) (32)
Targeting tumor neovasculature in non-small-cell lung cancer. (2013) (31)
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial (2022) (29)
The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. (2000) (28)
Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. (2001) (28)
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. (2018) (28)
Circulating soluble E-cadherin levels are of prognostic significance in patients with multiple myeloma. (2004) (27)
Sex hormone levels in the serum of patients with pancreatic adenocarcinoma. (1997) (27)
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial (2022) (27)
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy (2015) (26)
Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival (2007) (26)
Targeted therapy for oesophageal cancer: an overview (2008) (26)
The Role of E-Cadherin-Catenin Complex: More Than an Intercellular Glue? (2000) (25)
3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants (2015) (25)
EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review. (2016) (25)
Nonpharmacologic Interventions for Improving Sleep Disturbances in Patients With Lung Cancer: A Systematic Review and Meta-analysis. (2018) (25)
The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies (1994) (24)
Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis (2021) (24)
Proof of the Quantitative Potential of Immunofluorescence by Mass Spectrometry (2016) (24)
Histones and lung cancer: are the histone deacetylases a promising therapeutic target? (2013) (24)
Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay (2012) (24)
A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. (2002) (24)
Bladder cancer : biology, diagnosis, and management (1999) (24)
EGFR M utations in Non -small Cell Lung Cancer - Clinical Implications (2008) (23)
Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. (2002) (23)
Correlation of CYP1A1, GSTP1 and GSTM1 gene polymorphisms and lung cancer risk among smokers. (2012) (23)
Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. (2010) (23)
The clinical significance of molecular markers to bladder cancer. (2004) (23)
Prognostic significance of soluble adhesion molecules in Hodgkin's disease. (2004) (23)
Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial (2015) (23)
Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (23)
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS) (2012) (22)
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial (2018) (22)
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (2021) (22)
Mucins as immunogenic targets in cancer. (1999) (22)
Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy (2002) (22)
First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1. (2021) (22)
Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study (2021) (21)
Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. (2011) (21)
cancer xenograft model (2004) (21)
Skin cancer in the elderly. (2005) (21)
Expression patterns of the novel catenin p120cas in gastrointestinal cancers. (1999) (21)
Autoantibodies against insulin and β‐islet cells in pancreatic adenocarcinoma: A possible explanation for diabetes mellitus (1996) (21)
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. (2014) (21)
Recent Advances in Molecular Diagnosis of Thyroid Cancer (2011) (20)
Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. (1999) (20)
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. (2013) (20)
Venous Thromboembolism in Patients Diagnosed With Lung Cancer (2016) (20)
Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. (2002) (20)
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment (2014) (19)
Adjustable delivery of pro-angiogenic FGF-2 by alginate:collagen microspheres (2018) (19)
Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers. (2013) (19)
A phase I–II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens (2006) (19)
Biodistribution and Pharmacokinetics of 111In-DTPA-Labelled Pegylated Liposomes After Intraperitoneal Injection (2003) (19)
Prevalence, risk and aggravating factors of chronic venous disease: an epidemiological survey of the general population of Greece (2013) (18)
The Role of Tinzaparin in Oncology (2017) (18)
Effect of testosterone administration, pre- and postnatally, on the immune system of rats. (1995) (18)
Adhesion molecules as targets for the treatment of neoplastic diseases. (2006) (17)
Forming a Stress Management and Health Promotion Program for Women Undergoing Chemotherapy for Breast Cancer (2016) (17)
Cardiopulmonary exercise testing (CPET) as preoperative test before lung resection. (2012) (17)
Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core? (2010) (17)
Thymoma and radiation therapy: a systematic review of medical treatment (2013) (17)
Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan (2006) (17)
Renal oncocytoma: a case report and short review of the literature. (2008) (17)
Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. (2005) (17)
Pain and Anxiety versus Sense of Family Support in Lung Cancer Patients (2014) (17)
Challenges for the future modifications of the TNM staging system for head and neck cancer: case for a new computational model? (2009) (17)
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis. (2010) (16)
Pleural lavage cytology: where do we stand? (2014) (16)
The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives. (2015) (16)
Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience. (2008) (16)
Radioimmunotherapy of ovarian cancer. (1995) (16)
Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). (2015) (16)
Psychological correlates of sleep quality in lung cancer patients under chemotherapy: A single‐center cross‐sectional study (2019) (16)
Review. EGFR mutations in non-small cell lung cancer--clinical implications. (2008) (16)
Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy (2013) (16)
Tumour-induced neoneurogenesis and perineural tumour growth: a mathematical approach (2015) (16)
Optimizing diet and nutrition for cancer survivors: A review. (2017) (16)
Prognostic significance of erythropoietin expression in human renal cell carcinoma (2007) (16)
Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (2006) (15)
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG) (2017) (15)
Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study. (2015) (15)
H1N1-Induced Venous Thromboembolic Events? Results of a Single-Institution Case Series (2016) (15)
Autoantibodies in the serum of patients with gastric cancer: their prognostic importance. (1998) (15)
Time recall; future concept of chronomodulating chemotherapy for cancer. (2013) (15)
Thyroid autoantibodies and thyroid function in patients with gastric cancer. (1994) (15)
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer (2021) (15)
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). (2011) (14)
Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. (1997) (14)
Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. (2010) (13)
EGFR‐GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma (2016) (13)
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group (2021) (13)
Lung Cancer and Eye Metastases (2014) (13)
The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making. (2020) (13)
Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma (2018) (13)
Pulmonary hypertension after pneumonectomy for lung cancer (2014) (13)
A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report. (2006) (13)
The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes. (2001) (13)
Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model (2004) (12)
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (12)
High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. (2002) (12)
1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8). (2014) (12)
Heterogeneity in reporting venous thromboembolic phenotypes in COVID‐19: methodological issues and clinical implications (2020) (12)
The effects of Pythagorean Self-Awareness Intervention on breast cancer patients undergoing adjuvant therapy: A pilot randomized controlled trial (2019) (12)
The Role of Glutamine Supplementation in Thoracic and Upper Aerodigestive Malignancies (2015) (12)
A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer (2016) (12)
Tumors of the chest : biology, diagnosis and management (2006) (12)
Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer (2011) (12)
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. (2014) (11)
Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. (1999) (11)
Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion. (2002) (11)
The Use of Radiolabeled Somatostatin Analog Scintigraphy in the Staging of Small Cell Lung Cancer Patients (2007) (11)
The Role of Leptin in Cancer Pathogenesis (2013) (11)
Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study (2005) (11)
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. (2003) (11)
Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study (2018) (11)
Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced NonSmall Cell Lung Cancer: A Case Report (2016) (11)
Implementation of a Computerized System in an Oncology Unit (2007) (11)
Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227 (2020) (11)
Novel agents in the treatment of pancreatic adenocarcinoma. (2013) (11)
Rapid infusion of ibandronate in lung cancer patients with bone metastases. (2006) (10)
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (2012) (10)
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer. (2020) (10)
Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients (2011) (10)
Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. (2007) (10)
Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma (2005) (10)
Measurement of exhaled alveolar nitrogen oxide in patients with lung cancer: a friend from the past still precious today (2013) (10)
Severe delayed skin reaction during intradermal testing with β-lactam antibiotics. (2016) (9)
Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review. (2018) (9)
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. (2017) (9)
Translational Research in Pancreatic Cancer (2011) (9)
The Catastrophic HPV/HIV Dual Viral Oncogenomics in Concert with Dysregulated Alternative Splicing in Cervical Cancer (2021) (9)
Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer (2022) (9)
The effect of vertical banded gastroplasty on glucose-induced beta-endorphin response. (1998) (9)
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. (2013) (9)
Lung cancer patients' journey from first symptom to treatment: Results from a Greek registry. (2019) (9)
Soluble e-cadherin as a diagnostic and prognostic marker in gastric carcinoma (2013) (9)
2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study (2016) (9)
The clinical significance of cytology versus histology-based diagnosis in small cell lung cancer: a retrospective study. (2014) (9)
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality (2021) (9)
Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis. (2014) (8)
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. (2022) (8)
Prophylactic Cranial Irradiation in Patients with Small-Cell Lung Cancer (2006) (8)
The development of monoclonal antibody therapy in leukemias. (2001) (8)
PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost–effectiveness (2018) (8)
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection (2021) (8)
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy (2021) (8)
Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing (2021) (8)
Radiomics/Radiogenomics in Lung Cancer: Basic Principles and Initial Clinical Results (2022) (8)
Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. (2010) (8)
Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer. (1999) (8)
Sampling Versus Systematic Full Lymphatic Dissection in Surgical Treatment of Non-Small Cell Lung Cancer (2013) (8)
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). (2020) (7)
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer (2021) (7)
Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations. (2017) (7)
Primary malignant melanoma of the esophagus: report of two cases and review of the literature. (1999) (7)
Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment (2019) (7)
FOLFIRINOX: from the ACCORD study to 2014. (2014) (7)
NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. (2022) (7)
Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence. (2013) (7)
Carcinoma erysipeloides deriving from a primary cutaneous squamous cell carcinoma (2011) (7)
In vitro exposure of NK-92 cells to serum from patients with non-small cell lung cancer impairs their cytotoxicity. (2015) (7)
STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN. (2011) (7)
Autoantibodies against Cardiolipin in the Serum of Patients with Colorectal Adenocarcinoma:Their Prognostic Significance (1998) (7)
Endoscopic and endobronchial ultrasound-guided needle aspiration in the mediastinal staging of non-small cell lung cancer. (2013) (7)
Pancreatic cancer: updates on translational research and future applications. (2013) (7)
8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: the effect of chemotherapy. (2014) (7)
Serum β-Endorphin Levels in Morbidly Obese Patients: The Effect of Vertical Banded Gastroplasty (1998) (7)
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia (2015) (6)
Adrenal hyperresponsiveness to ACTH stimulation in women with polycystic ovary syndrome: an adrenarchal type of response. (1990) (6)
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group. (2007) (6)
Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (6)
Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). (2015) (6)
Many Voices in a Choir: Tumor-Induced Neurogenesis and Neuronal Driven Alternative Splicing Sound Like Suspects in Tumor Growth and Dissemination (2021) (6)
Structure and function of the oncologic boards in Greece. Description of the institutional and scientific frame; objective problems and difficulties. (2013) (6)
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping (2018) (6)
Pancreatic Neuroendocrine Tumors: Role of Novel Agents (2011) (6)
Implementing clinical protocols in oncology: quality gaps and the learning curve phenomenon. (2005) (5)
1313PImmune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK (2017) (5)
Paradoxical growth hormone response following thyroid-stimulating hormone administration in the polycystic ovary syndrome. (1989) (5)
New data for venous thromboembolism in patients with small cell lung cancer: A review (2018) (5)
Percutaneous radiofrequency ablation for unresectable colorectal liver metastases: time for shadows to disperse. (2009) (5)
Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer (2016) (5)
Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (5)
Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis. (2017) (5)
Epithelial mucin expression in bladder cancer: correlation with pathological and clinical parameters (2000) (5)
End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study (2019) (5)
Tumors of the Chest (2006) (5)
Preclinical research in treatment of pancreatic cancer. (2013) (5)
Usefulness of endobronchial ultrasound (EBUS) in the diagnosis of peripheral pulmonary lesions in a general hospital. (2013) (5)
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2. (2012) (4)
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance (2022) (4)
Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators (2020) (4)
Early Occurrence of Adverse Events in Hospitalized Patients With COVID-19 and Beneficial Effect of Anticoagulation (2021) (4)
Primary Sarcoma of the Lung – Prognostic Value of Clinicopathological Characteristics of 26 Cases (2020) (4)
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. (2019) (4)
A Rare Case of a Metastatic Lung Squamous Cell Carcinoma to the Large Bowel and the Liver (2021) (4)
The Role of GSK3β in T Lymphocytes in the Tumor Microenvironment (2020) (4)
Genetic factors affecting patient responses to pancreatic cancer treatment (2016) (4)
Acute Generalized Exanthematous Pustulosis Induced by Amoxicillin/Clavulanic Acid (2015) (4)
Anaphylaxis during skin prick testing for amoxicillin allergy. (2014) (4)
The role of biliary drainage in patients with pancreatic adenocarcinoma. (2014) (4)
Epithelioid hemangioendothelioma treated with bevacizumab: A case series (2015) (4)
Risk determination for pancreatic cancer. (2014) (4)
Modeling Proteolytically Driven Tumor Lymphangiogenesis. (2016) (3)
Soy allergy complicating disease management in a child with coeliac disease (2014) (3)
Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. (2015) (3)
Emmanuil Kondoleon: pioneer in surgical treatment for lymphedema. (2009) (3)
Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape. (2015) (3)
Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (3)
Second-line therapy in pancreatic cancer. (2013) (3)
Pharmacogenetics in pancreatic cancer. (2014) (3)
Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report (2018) (3)
Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer (2021) (3)
The use of novel oral anticoagulants in cancer patients with venous thromboembolism. (2016) (3)
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. (2018) (3)
Chromosomes 7/17 multiplication vs true polysomy: a crucial issue in lung and breast EGFR/HER2 dependent carcinoma cases. (2016) (3)
Clinical and Surgical-Pathological Staging in Early Non-Small Cell Lung Cancer (2013) (3)
The clinical significance of PD‑L1 in colorectal cancer (Review). (2021) (3)
Metastatic testicular cancer with massive gastrointestinal haemorrhage as initial presentation. (2002) (3)
A Novel Technique to Treat Air Leak Following Lobectomy: Intrapleural Infusion of Plasma (2016) (3)
Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer (2011) (3)
Do we need prophylactic anticoagulation in ambulatory patients with lung cancer? A review (2020) (3)
Pancreatic cancer in 2014. (2014) (3)
Nanoliposomal irinotecan for treating pancreatic cancer (2016) (3)
Noncoding RNA-mediated regulation of pyroptotic cell death in cancer (2022) (3)
Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer. (2006) (3)
Serum beta-endorphin levels in morbidly obese patients: the effect of vertical banded gastroplasty. (1998) (3)
Mesothelin and osteopontin (2013) (3)
Anaphylaxis during rapid oral desensitization to rifampicin. (2016) (3)
Cardiac injury and prognosis in COVID-19: Methodological considerations and updated meta-analysis (2020) (3)
Targeted therapy for cancer (2003) (3)
Human disease caused by Streptococcus alactolyticus: a case report of native valve infective endocarditis and review of the literature. (2020) (2)
Intensified Bimonthly Cisplatin With Bolus 5-Fluorouracil, Continuous 5-Fluorouracil and High-Dose Leucovorin (LV5FU2) in Patients With Advanced Gastrointestinal Carcinomas: A Phase I Dose-Finding and Pharmacokinetic Study (2004) (2)
Knowledge and Perceptions about COVID-19 among Health Care Workers: Evidence from COVID-19 Hospitals during the Second Pandemic Wave (2021) (2)
Biology of Tobacco and Smoking (2006) (2)
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung. (2016) (2)
O-094 Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable Non-small cell lung cancer (NSCLC) (2005) (2)
O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG) (2006) (2)
1086 Biochemical markers of bone remodeling as predictors of skeletal morbidity and outcome in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid (2009) (2)
Lung Metastasis From Fibrosarcomatous Dermatofibrosarcoma Protuberans of the Vulva: A Rare Case Report (2018) (2)
Exceptional antitumor responses beyond immune checkpoint inhibition in non-small cell lung cancer patients: insights into optimal therapy sequencing. (2019) (2)
Elevated serum VEGF levels in colorectal cancer patients correlate with poor survival (2001) (2)
Osteoporosis in patients with breast and prostate cancer: effect of disease and treatment modalities. (2013) (2)
Prognostic factors in pancreatic cancer. (2013) (2)
Thermal ablation may improve outcomes in patients with colorectal liver metastasis: a case-control study. (2017) (2)
Cytotoxic therapy of gastroenteropancreatic (GEP) tumors. (2002) (2)
Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer (2021) (2)
Molecular classification of non-small cell lung cancer using a four protein quantitative assay. (2010) (2)
Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes (2019) (2)
Clinical importance of [18F]fluorodeoxyglucose positron emission tomography/computed tomography in the management of patients with bronchoalveolar carcinoma: Role in the detection of recurrence (2013) (2)
PS01.30: Domain‐Specific c‐Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer: Topic: Pathology (2016) (2)
Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE75C as adjuvant chemotherapy in axillary lymph node-positive breast cancer (2008) (2)
Comparison of the sequential versus the alternate administration of cisplatin-etoposide and topotecan regimens as first line treatment in extensive stage small cell lung cancer (SCLC): A preliminary analysis of a multicenter randomized trial. (2004) (2)
Prolonged SARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy (2023) (2)
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders (2017) (2)
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). (2018) (1)
P-792 Phase II study of cisplatin plus etoposide over 3 days combinedwith irinotecan and early thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell lung cancer (SCLC), preliminary results (2005) (1)
Clinical utility of thoracic endosonography (EBUS/EUS-b) in mediastinal staging of patients with non-small cell lung cancer: comparison with integrated PET/CT—a real-life prospective study in Greece (2020) (1)
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 (2022) (1)
Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies. (2010) (1)
Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. (2011) (1)
The expanding new era of cancer immunotherapy (2016) (1)
Cow's Milk Protein Allergy Causing Persistent Elevation of Antitissue Transglutaminase Antibodies in a Child With Celiac Disease. (2015) (1)
Updates in management of ampullary carcinomas. (2014) (1)
Genomics and molecular analysis of RPL9 and LIAS in lung cancer: Emerging implications in carcinogenesis (2021) (1)
Treatment Adherence in Patients with Lung Cancer from Prospects of Patients and Physicians (2021) (1)
Pathophysiology and Management of Bone Metastases in Lung Cancer (2006) (1)
Molecular assays in detecting EGFR gene aberrations: an updated HER2-dependent algorithm for interpreting gene signals; a short technical report. (2016) (1)
3084 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes (2015) (1)
Pain Management in Palliative Care (2006) (1)
Non-specific autoantibodies in cardiomyopathies and myocardial infarction. (1995) (1)
Validation of the Khorana score in lung cancer patients: a new predictor of early mortality? (2018) (1)
Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS) (2012) (1)
Reliability and Validity of the Newly Diagnosed Breast Cancer Stress Scale in the Greek Population. (2020) (1)
Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study (2020) (1)
Efficacy of a Quail Eggs-Based Dietary Supplement for Allergic Rhinitis: Results of a Single-Arm Trial (2019) (1)
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway (2012) (1)
Giant tuberculin reaction associated with the homeopathic drug tuberculinum: a case report. (2014) (1)
Biomarkers in pancreatic neuroendocrine tumors. (2014) (1)
Treatment Pathways and Associated Costs of Advanced or MetastaticALKÃ¯Â¼Â Non-Small Cell Lung Cancer in Greece (2016) (1)
Economic evaluation of two therapeutic approaches in non small cell lung cancer: 45P (2016) (1)
Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer (2019) (1)
Computed tomography-guided radiofrequency ablation and microwave ablation of non-small cell lung cancer metastases: Safety and efficacy in a real-world cohort (2019) (1)
Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer (2014) (1)
Pulmonary nocardiosis associated with Cushing's disease: a case report. (2019) (1)
Treatment for Refractory Pancreatic Cancer (2011) (1)
Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: The Triumph of Radiobiology. (2021) (1)
Appropriate utilization of restricted antibiotics in a general hospital of a perfecture area in Greece. (2014) (1)
Intraperitoneal Radioimmunotherapy of Ovarian Cancer: Radiobiological Basis, Clinical Status and Future Prospects (2000) (1)
Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece (2023) (1)
First External Validation of the New COMPASS-CAT Risk Assessment Model for Ambulatory Patients with Breast, Colorectal, Lung or Ovarian Cancer (2018) (1)
Cabazitaxel (Cbz) versus topotecan in patients (pts) with small cell lung cancer (SCLC) that has progressed during or after first-line treatment with platinum-based chemotherapy: A randomized phase II study. (2013) (1)
The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview (2009) (0)
Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study (2016) (0)
P3.01-61 EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non Small Cell Lung Cancer (2018) (0)
The prognostic value of serum and pleural fluid vascular endothelial growth factor levels in advanced non-small cell lung cancer. (2015) (0)
82P ABSENCE OF HPV AND EBV IN LUNG ADENOCARCINOMA IN SINGAPORE (2007) (0)
Bevacizumab (Bv) in non small cell lung cancer (NSCLC) patients ≥75 years old with pre-existing cardiovascular disease (CVD): Experience at a tertiary referral center. (2013) (0)
Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC) (2008) (0)
Abstract 4643: A novel 3-biomarker quantitative protein assay predicts survival in stage I lung squamous cell carcinomas (2010) (0)
Comparative diagnostic accuracy of thoracic endosonography (EBUS/EUS-b) and integrated PET-CT in mediastinal staging of potentially operable patients with NSCLC (2020) (0)
Management of Cerebral Metastasis in Patients with Non-Small-Cell Lung Cancer (2006) (0)
Bortezomib in combination with gemcitabine (GEM) and cisplatin (CDDP) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC): A Hellenic Oncology Research Group multicenter phase II study. (2014) (0)
Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. (2010) (0)
Human papillomavirus and non small cell lung cancer: 29P (2016) (0)
3527 POSTER Correlation of GSTP1, GSTM1 and CYP1A1 Gene Polymorphisms and Lung Cancer Risk Among Smokers in a Greek Population (2011) (0)
Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade (2022) (0)
Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). (2018) (0)
Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy (2012) (0)
229P Clinical and laboratory markers of prognosis in lung cancer patients with hypercalcemia (2018) (0)
Factors affecting smoking cessation in patients with cancer (2017) (0)
Docetaxel-related peripheral neuropathy is a dose-dependent event; a retrospective study in a Greek population with NSCLC (2012) (0)
Albumin-bound paclitaxel (nab-P) may play an important role in the treatment of non-small-cell lung cancer (NSCLC) patients (2011) (0)
Advanced Lung Cancer Inflammation Index: Prognostic value in a retrospective lung cancer cohort. (2020) (0)
Erlotinib (E) in elderly pts with NSCL: Experience at a tertiary referral center (2013) (0)
2nd line chemotherapy in malignant mesothelioma: A center's experience: 212P (2016) (0)
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (2022) (0)
Brain metastases in lung adenocarcinoma: A retrospective study. (2015) (0)
Combination of cisplatin with the degramont regime in advanced GI cancer: a phase I study (1999) (0)
A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC). (2004) (0)
566PPROGNOSTIC SIGNIFICANCE OF TUMOUR-ASSOCIATED IMMUNE RESPONSE GENE EXPRESSION, ESR1 AND CLINICOPATHOLOGIC PARAMETERS IN STAGE II/III COLORECTAL CANCER: A TRANSLATIONAL RESEARCH STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG). (2014) (0)
Preneoplastic Lesions of the Lung (2006) (0)
Preclinical Research in Treatment of Pancreatic Cancer Highlights from the “ 2013 ASCO Annual Meeting ” . Chicago , IL , USA ; May 30-June 4 , 2013 (2013) (0)
42P THE PREDICTIVE SIGNIFICANCE OF LEPTIN, ADIPONECTIN, RESISTIN AND GHRELIN SERUM LEVELS AT DIAGNOSIS OF PATIENTS WITH SMALL CELL LUNG CANCER (2013) (0)
The action of Erythropoietin on venous thromboembolic events in lung cancer patients (2018) (0)
Head and Neck Cancer in the Elderly (2013) (0)
6606 POSTER Three drug regimen in SCLC-ED patients: a phase II study (2007) (0)
Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC). (2016) (0)
Cinnamon-Induced Contact Stomatitis: A Propos of Two Cases (2016) (0)
Antibiotic prophylaxis in chemotherapy-induced neutropenia in lung cancer patients (2011) (0)
39P USEFULNESS OF ENDOBRONCHIAL ULTRASOUND IN THE DIAGNOSIS OF PERIPHERAL PULMONARY LESIONS IN A GENERAL HOSPITAL (2013) (0)
A clinico-biological Risk Assessment Model for VTE in ambulatory patients with lung adenocarcinoma on chemotherapy issued from the ROADMAP study. (2016) (0)
P2.01-54 Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece (2019) (0)
Venous thromboembolic disease in patients with small cell lung cancer: incidence and clinicopathological risk factors (2020) (0)
Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC). (2012) (0)
Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece. (2022) (0)
Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated by bevacizumab with or without interferon therapy: Results from pooled analysis of AVATOR, CHANGE, and TRAIN studies. (2016) (0)
186P Thyroid toxicity as an immune-related adverse event in patients with non-small cell lung cancer during treatment with immune checkpoint inhibitors (2018) (0)
Locally advanced pancreatic cancer. (2013) (0)
A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients. (2015) (0)
CLC017 POSTER Study of the human clonal cell line NK-92 cytolytic ability in patients with non-small cell lung cancer and evaluation of the role of chemotherapy (2007) (0)
P3.01-95 EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer (2018) (0)
Primary lung sarcoma: A review of 25 cases in a single tertiary institution. (2011) (0)
Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors. (2021) (0)
Differential Influence of Lung Cancer Stage, Time from Diagnosis and Chemotherapy on Plasma and Cellular Biomarkers of Hypercoagulability. the Roadmap Study (2014) (0)
Smoking cessation in patients with cancer under real life conditions (2016) (0)
EP1.11-03 Diagnostic Evaluation of Patients with Solitary Pulmonary Nodules in a Tertiary Referral Center (2019) (0)
P3.01-94 Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer (2018) (0)
Modelization of the procoagulant properties of cancer cells and the alterations of the effectiveness of the anticoagulant agents. (2016) (0)
Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID Syndrome (2022) (0)
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis (2012) (0)
High Expression of MammalianTarget of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma (2009) (0)
Obesity and Mortality Among Patients Diagnosed With COVID-19 (2021) (0)
The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer (2012) (0)
Gene therapy strategies for lung cancer. (2002) (0)
Bevacizumab (Bv) in elderly pts with NSCLC: Experience at a tertiary referral center (2013) (0)
Clinical examination practices and perceptions in the era of COVID-19 (2021) (0)
446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers (2016) (0)
The Role of Fluorodeoxyglucose Standardized Uptake Value in Diagnosis, Staging and Restaging of Non-Small Cell Lung Cancer (2016) (0)
Non-coding RNAs regulate mitochondrial dynamics in the development of gastric cancer (2023) (0)
Rare Tumors of the Chest (2006) (0)
The Immunotherapy of Bladder Cancer (2002) (0)
The Khorana score as a predictor of mortality in lung adenocarcinoma (2018) (0)
PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study. (2016) (0)
111P EFFECTIVENESS OF MESOTHELIN FAMILY PROTEINS AND OSTEOPONTIN FOR MALIGNANT MESOTHELIOMA (2013) (0)
Quality of Life in patients with lung cancer after endobronchial intervention for malignant central airway obstruction (2019) (0)
Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures (2020) (0)
Nsclc and egfr activating mutations (EGFRm+). Experience from a reference center in Greece (2017) (0)
Efficacy and safety of bevacizumab biosimilar FKB238 versus originator bevacizumab: Results from a phase III trial in patients with non-squamous non-small cell lung cancer (NS-NSCLC). (2020) (0)
CureCancer Digital Platform in Clinical Oncology Practice Facilitates Patients’ Self-data Recording, Communicating, Treatment Adherence, “Distancing Interventions” During Covid-19 and Reduces Costs. A Feasibility and Satisfaction Study. (2022) (0)
Abstract 339: Resistance to trastuzumab is associated with alpha-smooth muscle actin expression in the stroma of patients with HER2+ breast cancer (2021) (0)
PMD115 - THE DIAGNOSTIC METHODS AND COST OF LUNG CANCER IN GREECE (2018) (0)
Prognostic value of circulating tumor cells in non-small cell lung cancer. (2017) (0)
Efficacy of Tocilizumab in Severely Ill COVID-19 Patients With Rapid Respiratory Deterioration: A Single Center Experience During the Third Pandemic Wave in Greece (2023) (0)
PO-68 Evolution of long term use of tinzaparin (6 months) in patients with DVT: a prospective study of our clinic (2010) (0)
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia (2022) (0)
Response to the letter to the editor: “New data for venous thromboembolism in patients with small cell lung cancer: A review” (2018) (0)
Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer (2018) (0)
Hypersensitivity To Docetaxel: Retrospective Study And Desensitization Protocol (2012) (0)
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial (2015) (0)
LUX-Lung 8: A Global Phase III Trial of Afatinib (A) vs Erlotinib (E) as Second-Line Treatment in Patients (Pts) With Advanced Squamous Cell Carcinoma (SCC) of the Lung Following First-Line Platinum-Based Chemotherapy (2015) (0)
Thymic tumours: Diagnostic and therapeutic approach (2012) (0)
Accelerated hypofractionated radiotherapy for advanced lung cancer (2017) (0)
Small cell lung cancer patients and venous thromboembolism: The need of anticoagulation treatment (2018) (0)
Abstract 937: Quantitative assessment of CD200 and CD200R expression in lung cancer (2020) (0)
The intention of smoking cessation in cancer patients (2017) (0)
P2.04-008 ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy (2017) (0)
Efficacy of a quail eggs‐based dietary supplement for allergic rhinitis: 536 (2019) (0)
9323 POSTER Enhanced in Vitro and in Vivo Cytotoxicity of Combined Vaccinia Virus Strain GLV-1h68 and Chemotherapy in Melanoma (2011) (0)
Lungful: An observational prospective study to assess the molecular epidemiology of EGFR mutations upon progression on or after first line EGFR-TKI therapy, in real-life clinical settings in Greece. (2020) (0)
Effects of Smoking Cessation on lung cancer chemotherapy. (2017) (0)
Garon et al 2014 Lancet Supplument (2014) (0)
Identification of clinical variables and biomarkers of hypercoagulability for VTE risk evaluation in ambulatory patients with lung adenocarcinoma on chemotherapy: The ROADMAP study. (2016) (0)
Superior vena cava syndrome in lung cancer patients: How to prevent its venous thromboembolism complications (2018) (0)
Commentary on Section IV (2002) (0)
Biological predictors of third-line treatment outcomes in patients with advanced non-small cell lung cancer. (2020) (0)
9045 Serum metastin is not involved in metastatic potential of non-small cell lung cancer (NSCLC) (2009) (0)
Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study. (2020) (0)
Prospective Assessment of The Accuracy, Reliability and Cost-Effectiveness of Staging Non-Small Cell Lung Cancer (NSCLC) Only with The Combination of Pet/Ct and Brain MRI (2017) (0)
Immunohistochemical Expression of Angiogenesis and cell-adhesion Markers in Surgical and Autopsy NSCLC Tissue samples: Correlation with Clinicopathologic parameters and survival. (2016) (0)
Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals (2018) (0)
Prolonged efficacy of sunitinib in a cohort of patients with metastatic renal cancer: A retrospective analysis from the Hellenic Cooperative Oncology Group. (2014) (0)
The Role of Genetics in Sporadic GEP-NETs: A Comprehensive Review of the Literature (2017) (0)
Management of Malignant Pleural Effusions (2006) (0)
Kit formulation of Bevacizumab, an anti-VEGF monoclonal antibody, and consequent labelling with Rhenium-188: initial in vitro and in vivo studies (2008) (0)
Additional file 8 (2012) (0)
PO-69 Evolution of long term use of tinzaparin (12 months) in patients with pulmonary embolism: a prospective study of our clinic (2010) (0)
Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (2022) (0)
Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study (2020) (0)
Bone metastases in patients with small cell lung carcinoma: Rate of development, modality of treatment, and their impact on survival. (2015) (0)
AB 60. Nitric oxide measurements in lung cancer (2012) (0)
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. (2015) (0)
Efficacy and safety of everolimus in advanced low- to intermediate-grade neuroendocrine tumors. (2015) (0)
Erlotinib (E) in non small cell lung cancer (NSCLC) patients (pts) ≥75 years old with comorbidities (cM): Experience at a tertiary referral center. (2013) (0)
Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study ‘LUNGFUL’ (2023) (0)
Thermal ablation may prolong survival in colorectal liver metastasis over chemotherapy alone: a case-control analysis (2015) (0)
Microbiomics in Collusion with the Nervous System in Carcinogenesis: Diagnosis, Pathogenesis and Treatment (2021) (0)
Abstract 2710: SRC/STAT related parameters might predict for prognosis and response to targeted treatments in squamous cell carcinomas of the head and neck (SCCHN) (2010) (0)
Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer (2016) (0)
Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer (2022) (0)
EP1.01-69 Safety and Efficacy of Percutaneous Computed Tomography-Guided Thermal Ablation of Non-Small Cell Lung Cancer Metastases (2019) (0)
DAXAS and COPD Correlation with Cancer. (2014) (0)
Novel Cytotoxic Agents in the Management of Lung Cancer (2006) (0)
Treatment of Percistent Blepharitis and Keratoconjuctivitis with Intraocular and Topical Use of Tacrolimus 0.03% Ointment (2016) (0)
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond (2023) (0)
Prognostic value of Nutric score in critically ill patients with lung cancer (2020) (0)
3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants (2015) (0)
International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients (2012) (0)
Successful paremteral rapid desensitization to docetaxel (2003) (0)
CureCancer Digital Platform In The Routine Clinical Oncology Practice Facilitates Patients’ Self-Data Recording, Communicating With Health Care Professionals, Treatment Adherence And “Distancing Interventions” During Covid-19 And Reduces Costs. A Feasibility And Satisfaction Study*. (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Konstantinos Nikolaos Syrigos?

Konstantinos Nikolaos Syrigos is affiliated with the following schools:

Konstantinos Nikolaos Syrigos's Academic­Influence.com Rankings

Why Is Konstantinos Nikolaos Syrigos Influential?

Konstantinos Nikolaos Syrigos's Published Works

Published Works

What Schools Are Affiliated With Konstantinos Nikolaos Syrigos?

Konstantinos Nikolaos Syrigos's AcademicInfluence.com Rankings